Acute Asthma - Part 1: The First Hour
Recognising severity, treating aggressively, and changing the trajectory before the crash
Acute asthma in the emergency department is not simply a problem of airflow—it is a problem of time, trajectory, and therapeutic intensity.
Every exacerbation follows a trajectory.
Your role is to alter that course early.
What is reversible can become irreversible.
Patients do well when we:
Recognise severity early
Deliver adequate-dose bronchodilation immediately
Initiate systemic anti-inflammatory therapy without delay
They deteriorate when we:
Underestimate severity
Undertreat early bronchospasm
Focus on oxygenation instead of ventilation
The first hour is not about observation—it is about decisive intervention.
Framing the Acute Attack: Pathophysiology That Drives Decisions
An acute asthma exacerbation represents acute-on-chronic airway inflammation with superimposed broncho-constriction.
Three processes act simultaneously:
Airway smooth muscle constriction
Mucosal edema
Mucus plugging
These lead to:
Increased airway resistance
Prolonged expiration
Dynamic hyperinflation
Ventilation–perfusion mismatch
Progressive hypercapnia
This physiological cascade—particularly air trapping and auto-PEEP—is central to deterioration in severe asthma (Mein & Ferrera, 2025).
Asthma is fundamentally a disease of impaired expiration, not inspiration.
Severity Assessment: Why Clinical Impression Fails
Classic signs of severe asthma include:
Tachypnea ≥30/min
Tachycardia ≥120/min
Inability to speak full sentences
Accessory muscle use
Diaphoresis
Pulsus paradoxus
However:
Up to 50% of patients with severe airflow obstruction lack classic signs (Cahill et al., 2025).
This makes objective assessment essential.
Objective assessment
Peak Expiratory Flow (PEF)
<50% predicted → severe
<25% or <150 L/min → risk of hypercapnia
PEF is a critical tool for:
Detecting occult severity
Monitoring response
Risk stratification (Cahill et al., 2025)
Oxygenation
Pulse oximetry for all patients
SpO₂ <90% → life-threatening exacerbation
Marked hypoxemia should prompt evaluation for complications (Cahill et al., 2025).
⚠️ Critical physiological warning
Even a normal PaCO₂ in acute asthma indicates impending respiratory failure, reflecting reduced alveolar ventilation (Cahill et al., 2025).
The First 5–10 Minutes: High-Stakes Decisions
Early ED management should rapidly determine:
Severity
Response to initial therapy
Need for escalation or ventilatory support
Simultaneously, clinicians must consider alternative or coexisting diagnoses such as pneumothorax, pulmonary embolism, or anaphylaxis (Mein & Ferrera, 2025; Cahill et al., 2025).
💨 Core ED Management: Evidence-Based Therapy
Modern management converges on three interventions:
Oxygen + bronchodilators + systemic corticosteroids
This approach is consistent across GINA, UpToDate, EMCrit, EM Cases, and CorePendium (GINA, 2025; Cahill et al., 2025; Farkas, 2024; McFarlin et al., 2026).
1. Oxygen: Precision, Not Excess
Target:
SpO₂ 92–95% (most adults)
≥95% in pregnancy
88–92% in asthma–COPD overlap
Excess oxygen may worsen hypercapnia and V/Q mismatch, particularly in overlap syndromes (McFarlin et al., 2026).
Pulse oximetry may overestimate saturation in certain populations, necessitating clinical correlation (Cahill et al., 2025).
2. Short-Acting Beta₂-Agonists (SABA)
Mechanism:
Broncho-dilation via β₂-receptor stimulation
Dosing:
Nebulised:
Albuterol 2.5–5 mg every 20 minutes × 3
MDI with spacer:
4–8 puffs every 20 minutes × 3
Severe cases:
Continuous nebulisation 10–15 mg/hour (McFarlin et al., 2026)
Delivery method:
MDI with spacer provides equivalent efficacy to nebulisation with lower aerosolisation risk (Cahill et al., 2025).
Adverse effects:
Tachycardia
Tremor
Hypokalemia
Lactic acidosis
These effects are expected and should not limit adequate dosing.
Paradigm shift:
SABA-only therapy is associated with worse outcomes and is no longer recommended (GINA, 2025).
3. Anticholinergics (Ipratropium)
Dosing:
500 mcg nebulised every 20 minutes × 3 doses
Benefit:
Improved lung function
Reduced hospital admission in moderate–severe exacerbations (McFarlin et al., 2026)
Clinical nuance:
Benefit is limited to early management and not required after stabilization.
4. Systemic Corticosteroids
Role:
Reduce airway inflammation and prevent relapse
Indications:
Moderate–severe exacerbations
Incomplete response to bronchodilators
Timing:
Within the first hour (Cahill et al., 2025)
Systemic corticosteroids are one of the few interventions that truly modify the trajectory of an asthma exacerbation when given early. Importantly, evidence consistently shows that oral steroids are as effective as intravenous therapy in most patients, with no meaningful difference in lung function, admission rates, or length of stay—making the oral route the preferred, simpler, and more cost-effective option when feasible.
Among agents, dexamethasone, prednisolone/prednisone, and methylprednisolone offer comparable clinical outcomes; however, dexamethasone stands out for its shorter course, better tolerability, and improved compliance, while prednisolone remains widely used due to familiarity and cost.
In practice, the choice of drug and route matters far less than ensuring early administration of an adequate dose, as timely steroid therapy is what prevents progression from reversible airway inflammation to fixed, refractory disease.
Dosing:
Prednisone 40–60 mg PO daily for 5–7 days
Methylprednisolone 60–125 mg IV (McFarlin et al., 2026)
Evidence insights:
Early steroids reduce hospitalisation and relapse (Cahill et al., 2025)
High-dose regimens offer no additional benefit and increase adverse effects (Mein & Ferrera, 2025)
Emerging alternative:
Dexamethasone
12–16 mg PO/IV once ± repeat dose
Offers:
Comparable efficacy
Improved adherence (McFarlin et al., 2026)
🔥 Common Early Pitfalls
Delayed steroid administration
Inadequate bronchodilator dosing
Reliance on auscultation alone
Failure to use PEF
Uncontrolled oxygen delivery
Discharge on SABA-only therapy
Clinical Synthesis
Acute asthma management is about trajectory modification.
Early recognition + aggressive treatment
= prevention of respiratory failure
Part 1 Take-home
The first hour determines the next 24 hours.
📌 Coming in Part 2:
Refractory asthma
Magnesium, NIV, rescue therapies
The crashing asthmatic
Ventilator strategy
Discharge & relapse prevention
📚 References (AMA Style)
Mein SA, Ferrera MC. Management of asthma and COPD exacerbations in adults in the ICU. Chest Crit Care. 2025;3(1):100107.
Cahill KN, Dixon AE, Zachrison KS. Acute exacerbations of asthma in adults: Emergency department and inpatient management. UpToDate. Updated September 2025.
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2025 update.
McFarlin A, Chan C, Winters M, et al. Asthma in adults. EM:RAP CorePendium. Updated February 2026.
Farkas J. Asthma. EMCrit Project. January 2024.
Helman A, Sommer L, Mal S. The crashing asthmatic: Recognition and management of life-threatening asthma. Emergency Medicine Cases. April 2024.
Morris MJ, Mosenifar Z. Asthma guidelines: Guidelines summary. Medscape. Updated March 2026.